GeoVax Labs terminates CEO David A. Dodd, who remains board chairman
GeoVax Labs terminated CEO David A. Dodd for non-compliance with board directives, effective immediately. Dodd remains a board director and chairman. The company stated the termination was for cause, but this has not been legally determined. GeoVax will not pay severance or vest options unless the cause determination is overturned, which could entitle Dodd to compensation. According to the company, the decision was disclosed in an SEC filing.
How this was made

The 30-second read
Why it matters
The termination is a corporate governance event that typically depresses share price, especially for small caps where leadership is critical.
Market read
The news is a primary disclosure of a material executive change, likely prompting short‑term downside for GOVX.
What to watch
Potential for a rapid appointment of an experienced interim CEO could stabilize the stock.
Background
GeoVax Labs (GOVX) is a clinical‑stage biotech focused on vaccine development. The 8‑K filing disclosed the board’s decision to terminate the CEO for cause, with Dodd remaining as chairman.
Ticker impact
GeoVax Labs filed an 8‑K announcing the immediate termination of CEO David A. Dodd for cause, with no severance.
likely downward pressure as market prices in leadership uncertainty
The abrupt removal of the CEO without severance signals possible internal conflict and may raise concerns about governance, prompting short-term price decline.
Market effects
Minimal; biotech sector may see slight caution on governance risks.
U.S. biotech micro‑cap segment may experience modest pullback.
Limited to investors tracking small‑cap biotech news.
Counterpoint
If the board's decision reflects a strategic shift, new leadership could eventually unlock value.
Key entities
- ExecutiveDavid A. Dodd
President, CEO, and Board Chairman of GeoVax Labs, terminated for cause.
- CompanyGeoVax Labs
Biotech firm filing the 8‑K announcing the executive change.
